皮肤冠状动脉干预后与抗血栓治疗相关的出血风险的性别差异
Yoshimi Numao1, Saeko Takahashi2, Yoko M Nakao3
1Department of Cardiology, Itabashi Chuo Medical Center Tokyo Japan.
Circulation reports
|April 12, 2024
概括
患有心血管疾病的女性在接受抗血栓治疗的穿皮冠状动脉干预 (PCI) 后可能有更高的出血风险. 目前的证据缺乏性别特定的建议,这凸显了需要进一步研究的必要性.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 抗血栓治疗对于心血管疾病 (CVD) 的二次预防至关重要.
- 患有心血管疾病的女性可能在经皮冠状动脉干预 (PCI) 后出现出血增加,但在临床试验中代表性不足.
- 针对性别特异性抗血栓治疗建议的证据有限.
研究的目的:
- 审查有关PCI后抗血栓治疗相关的出血并发症的性别差异的现有证据.
- 确定关于女性最佳抗血栓策略的知识差距.
主要方法:
- 在PubMed搜索中搜索了有关女性出血并发症和抗血栓治疗的英语文章.
- 文献综述侧重于PCI后的抗血小板治疗,抗凝血和三重抗血栓治疗 (TAT).
主要成果:
- 女性可能具有更高的血小板反应能力,但临床含义尚不清楚.
- 妇女在PCI后使用抗血小板疗法显示急性出血风险升高,但没有观察到慢性阶段差异.
- 考虑年龄,功能和体重对于女性的抗血小板剂量至关重要.
- 直接口服抗凝剂可能为PCI后的女性提供比华法林更低的出血风险.
- 没有足够的证据来指导性特异性TAT持续时间或心房的女性的治疗方案.
结论:
- 目前关于PCI后出血的性别差异的研究结果不支持针对女性的特定治疗建议.
- 进一步的研究是必不可少的,以建立最佳的针对PCI后妇女的抗血栓治疗.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
3.4K
08:13Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
6.2K
相关概念视频
01:24Disorders of Hemostasis
881
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
881
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522